People wit

People with SARS-CoV-2 antibodies have a strong response to a single dose of mRNA COVID-19 vaccine: Study

Healthcare workers with previous coronavirus disease 2019 (COVID-19) infection, based on laboratory-confirmed serology testing, had higher antibody titre responses to a single dose of the mRNA COVID-19 vaccine than those who were not previously infected, according to a study published in JAMA. Antibody titres started peaking at 7 days in people who had been previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and at 14 days, higher titres and neutralisation were achieved compared with people who did not previously contract the virus. “Persons who have ha...

High Incidence of Kidney Injury That Leads to CKD After Heart Transplantation

Patients undergoing heart transplantation are at an increased risk of acute kidney injury that commo...

Reduction in COVID-19 patients requiring mechanical ventilation following national vaccination ...

Findings published in the US Centers for Disease Control and Prevention's (CDC) latest Morbidity and...


Suggested videos

Search:
Date
Filters:
Global Per
8:14

Global Perspectives on Breast Cancer Care during the COVID-19 Pandemic how BC was managed and lessons Learned

Presenter: Lidia Schapira
Oncology
SABCS 2020
Effect of
4:54

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Presenter: John Kuruvilla
Hematology
ASH 2020
Optimal Du
3:55

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Presenter: Dennis Kim
Hematology
ASH 2020
Novelties
8:45

Novelties on the treatment of Multiple Myeloma and Plasma Cell Disorders

Presenter: Joseph Mikhael
Hematology
ASH 2020
Omitting R
5:14

Omitting Radiation Therapy After Breast-Conserving Surgery May Not Impact 10-year Survival Rates for Older Patients With HR-positive Breast Cancer

Presenter: Ian Kunkler
Oncology
SABCS 2020
Comprehens
14:08

Comprehensive summary of novel multiple myeloma data from ASH2020

Presenter: Andrzej Jakubowiak
Hematology
ASH 2020
Women Who
5:46

Women Who Undergo Mastectomy and Reconstructive Surgery May Be at Risk of Becoming Persistent Drug Users

Presenter: Jacob Cogan
Oncology
SABCS 2020
Comparison
7:32

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Presenter: Amer Zeidan
Hematology
ASH 2020
Polatuzuma
5:05

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Presenter: Giuseppe Gritti
Hematology
ASH 2020
From Trial
13:26

From Trials to Bedside: Filling the Gaps in Implementing Evidence-based Care

Presenter: Paul Whelton
Cardiology
AHA 2020
Updated mo
2:25

Updated monarchE Trial Data Shows Abemaciclib Continues to Benefit Patients With High-risk, HR-positive, HER2-negative, Earlystage Breast Cancer

Presenter: Priya Rastogi
Oncology
SABCS 2020
Highlights
9:15

Highlights of the Late-Breaking Abstracts Session of ASH 2020

Presenter: Christopher Flowers
Hematology
ASH 2020
Ruxolitini
5:24

Ruxolitinib Vs Best Available Therapy in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease: Primary Findings from the Phase 3, Randomized REACH3 Study

Presenter: Robert Zeiser
Hematology
ASH 2020
What are t
3:32

What are the trends in lymphoma therapy?

Presenter: Catherine Diefenbach
Hematology
ASH 2020
Effects of
11:38

Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial

Presenter: Darrell Triulzi
Hematology
ASH 2020
A Multi-Ce
3:33

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplan

Presenter: Corey Cutler
Hematology
ASH 2020
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology